For the third quarter of 2008, Baxter expects sales growth of 6 to 8 percent, excluding the impact of foreign exchange, and earnings per diluted share, before any special items, of $0.81 to $0.83.
A webcast of Baxter's second quarter conference call for investors can be accessed live from a link on the company's website at http://www.baxter.com beginning at 7:30 a.m. CDT on July 17, 2008. Please visit Baxter's website for more information regarding this and future investor events and webcasts, including investor presentations.
Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning the
company's financial results. The statements are based on assumptions about
many important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking statements:
demand for and market acceptance risks for new and existing products, such
as ADVATE, and other technologies; future actions of regulatory bodies and
other governmental authorities, including the FDA and foreign counterparts,
that could delay, limit or suspend product development, manufacturing or
|SOURCE Baxter International Inc.|
Copyright©2008 PR Newswire.
All rights reserved